U.S. Pharma Stock News

Energizer Holdings, Inc. recently reaffirmed its second-quarter and full-year 2026 guidance, expecting a 4% to 5% organic net sales decline in the quarter but flat to slightly higher organic net sales across its Batteries and Lights and Auto Care segments for the full year, while its Board declared a US$0.30 per-share dividend payable in March 2026. Despite margin pressures from tariffs and operational inefficiencies, Energizer exceeded adjusted earnings expectations, generated strong cash...

Market context and recent performance Corvus Pharmaceuticals (CRVS) has drawn investor attention after a sharp share price move, with the stock up 7.35% in the latest session and posting significant gains over the past month. See our latest analysis for Corvus Pharmaceuticals. The latest move sits within a very strong run, with a 30 day share price return of 201.33% and year to date share price return of 179.51%. The 1 year total shareholder return of 306.76% and very large 3 year total...

UGI (UGI) is back in focus after reporting first quarter results that included a 5% year over year EBIT increase, the completion of its LPG portfolio rationalization, and a Moody’s outlook upgrade for AmeriGas. See our latest analysis for UGI. Despite the recent EBIT progress and LPG portfolio clean up, UGI’s share price has been under some pressure in the short term, with a 1 day share price return of a 2% decline and a 7 day share price return of a 7.6% decline, while the 90 day share price...

Neogen Corporation recently initiated a voluntary recall of all in-date lots of its Vet HYCOAT Hyaluronate Sodium Sterile Solution for animals, after microbial contamination was detected in certain 10 mL/50 mg vials and adverse events were reported in horses when used off-label as intraarticular injections. Although no adverse events have been reported when HYCOAT is used as labeled for topical wound management, the company has extended the recall to additional lot sizes and is working with...

Nurix Therapeutics (NRIX) is in focus after reporting full year 2025 earnings that paired revenue of US$83.98 million with a wider net loss of US$264.46 million, alongside a new US$98.8 million shelf registration. See our latest analysis for Nurix Therapeutics. The latest earnings release and shelf registration have arrived after a volatile stretch, with a 31.03% 90 day share price return contrasting with a 12.69% 30 day decline and a 6.44% 1 year total shareholder return fall. This suggests...

The Bancorp, Inc. recently reported full-year 2025 results, with net interest income of US$375.51 million, net income of US$228.21 million, and diluted EPS from continuing operations of US$4.92, alongside materially higher fourth-quarter net charge-offs of US$39.21 million versus US$18.81 million a year earlier. At the same time, the company initiated 2026 earnings guidance of US$5.90 EPS, targeted at least US$1.75 EPS for fourth-quarter 2026, and completed a US$149.99 million buyback of...

Alvotech recently reported positive top-line results from a pharmacokinetic study for AVT80, its subcutaneous biosimilar candidate to Entyvio, and also finalized new global patent settlements and commercial entry timelines for its aflibercept biosimilar AVT06. In parallel, Alvotech entered expanded supply and commercialization agreements with Sandoz across Canada, Australia and New Zealand, signalling a broader role as a development and manufacturing partner for multiple biosimilars. We’ll...

What Yelp’s Recent Share Performance Tells Investors Yelp (YELP) is drawing attention after a period of weak share performance, with the stock showing negative returns over the past week, month, past 3 months, year, and on a 3 and 5 year basis. See our latest analysis for Yelp. At the latest share price of $24.42, Yelp’s 7 day share price return of a 10.88% decline and year to date share price return of a 19.14% decline sit alongside a 1 year total shareholder return of a 38.43% loss. This...

Crown Castle Inc. reported past fourth-quarter 2025 revenue of US$1,072 million and full-year 2025 revenue of US$4,264 million, alongside a swing from a very large prior-year net loss to net income of US$444 million, while outlining plans to sell its fiber and small cell businesses and cut about 20% of its workforce. An interesting wrinkle for investors is that Crown Castle paired this restructuring with plans to maintain its US$4.25 annual dividend, authorize US$1 billion in share...

Leadership transition and what it may mean for investors Louisiana-Pacific (LPX) has drawn fresh attention after announcing a leadership reshuffle, with F. Nicholas Grasberger III set to become independent Chairperson and CEO-elect Jason P. Ringblom joining the Board as director. This shift in Board roles, alongside the retirement of current Chairperson and CEO W. Bradley Southern, raises questions about how governance, capital allocation and long term priorities could evolve for existing and...

In late January 2026, Corebridge Financial introduced the Invesco New Economy Index within its Power Select Index Annuities, offering indexed exposure linked to technology-focused Invesco QQQ ETF and cryptocurrency-focused Invesco Galaxy Bitcoin ETF while maintaining principal protection features. This move blends traditional index annuity benefits with access to innovative themes such as cloud computing and bitcoin, potentially repositioning Corebridge in the retirement-income solutions...

uniQure N.V. recently reported updated preliminary safety and exploratory efficacy data from 11 patients in its ongoing Phase I/IIa trial of AMT-191, an investigational AAV gene therapy for Fabry disease, showing elevated α-galactosidase A activity across all three dose cohorts and a manageable safety profile. An interesting early signal is that several participants have been able to discontinue enzyme replacement therapy, hinting at the potential real-world impact of a one-time gene therapy...

Heightened optimism around upcoming earnings has pulled US Foods Holding (USFD) into focus as investors weigh expectations for higher revenue, a possible earnings beat, and management’s margin and network improvement efforts. See our latest analysis for US Foods Holding. Those expectations are coming on the back of strong momentum, with the share price at $90.33 and recent share price returns of 8.02% over 7 days, 19.50% over 30 days, and 24.94% over 90 days. The 1 year total shareholder...

NOV Inc. recently reported fourth-quarter 2025 results showing revenue of US$2,277 million and a net loss of US$78 million, alongside guidance for a 1% to 3% year-over-year revenue decline in the first quarter of 2026. Despite weaker earnings, NOV has tightened its acquisition criteria, completed a share buyback of 36,959,834 shares for US$544.64 million, and signaled interest in targeted M&A aligned with its core businesses. Next, we’ll examine how NOV’s stricter acquisition approach and...

Mister Car Wash has recently reported that weak same-store sales over the past two years and elevated net debt levels are pressuring its operations and funding flexibility. While returns on capital are improving as management focuses on higher-quality investments, the combination of sluggish traffic and high leverage raises questions about how the business will fund future growth without diluting existing shareholders. Next, we’ll look at how concerns over Mister Car Wash’s high leverage...

Granite Construction announced in January 2026 that it had been selected to rehabilitate an eight-mile stretch of U.S. Highway 101 near King City in Monterey County, California, a federally funded infrastructure project estimated at about US$20,000,000 and scheduled to run from late first quarter 2026 to first quarter 2027. An interesting aspect of this contract is Granite’s plan to supply roughly 37,830 tons of asphalt from its own Coalinga Asphalt Plant, highlighting the company’s...

What Pulse Biosciences’ Recent Move Might Be Telling You Pulse Biosciences (PLSE) has attracted fresh attention after a sharp recent move in its share price, with short term returns outpacing its past year performance and prompting investors to reassess the risk and reward trade off. See our latest analysis for Pulse Biosciences. The 51.6% 1 day share price return, on top of a 35.4% 90 day share price return and a 55.0% year to date share price return, contrasts with a 7.2% decline in 1...

FedEx (FDX) has been in focus after a sharp move higher, as investors rotated into industrial names and looked ahead to the company’s 2026 Investor Day along with its upcoming multi-year efficiency and pricing plan. See our latest analysis for FedEx. The recent jump sits on top of a broader upswing, with a 90 day share price return of 45.43% and a 1 year total shareholder return of 47.60%. This suggests momentum has been building as FedEx rolls out new digital tools, data partnerships, fresh...

Piper Sandler Companies recently reported strong fourth-quarter and full-year 2025 results, with Q4 revenue of US$666.99 million and net income of US$113.97 million, and declared both a US$5.00 per share special dividend and a US$0.70 quarterly dividend payable in March 2026. The company paired these results with a four-for-one stock split and the ongoing build-out of its investment banking platform, including the acquisition of G Squared and senior hires in energy and power. Against this...

In recent commentary, Vita Coco Company highlighted its evolution into a profitable global functional hydration brand built on an asset-light supply chain, supported by strong guidance for 2025 and growing international reach. An interesting angle for investors is how Vita Coco’s underdog roots, partnership with Keurig Dr Pepper, and disciplined expansion have created a scalable platform for new products and markets. With this backdrop, we’ll examine how Vita Coco’s asset-light supply...

Principal Financial Group is approaching an upcoming earnings report with analysts expecting quarterly earnings per share of US$2.23 and revenues of US$4.11 billion, both higher than the same period a year earlier. Despite JPMorgan downgrading the stock from Overweight to Neutral in the past, the bank highlighted Principal’s stronger business mix, lower tail risk, higher return on equity, and better free cash flow versus many life insurance peers, with potential upside from healthier asset...

Manhattan Associates recently reported its fourth-quarter and full-year 2025 results, with revenue of US$270.39 million for the quarter and US$1.08 billion for the year, alongside net income of US$51.95 million for the quarter and US$219.95 million for the year. At the same time, the company issued 2026 guidance calling for total revenue of US$1.13 billion to US$1.15 billion and a GAAP operating margin of 24.1% to 24.7%, while continuing to return capital through share repurchases. We will...

StepStone Group (STEP) is back in focus after quarterly results came in ahead of market expectations, supported by strong fee related earnings, record Private Wealth subscriptions, and growing partnerships and product expansion. See our latest analysis for StepStone Group. The latest earnings surprise appears to have checked a recent pullback, with the 1 day share price return of 5.5% partly offsetting a 30 day share price return decline of 13.4%, while a 3 year total shareholder return of...

NetScout Systems, Inc. recently reported its third-quarter and nine-month fiscal 2026 results, showing quarterly revenue of US$250.68 million and net income of US$55.14 million, and it modestly raised full-year guidance for both revenue and GAAP diluted earnings per share. Beyond the headline numbers, the company’s improved profitability and guidance were underpinned by strength in cybersecurity and observability solutions, including new capabilities for Wi‑Fi 7 monitoring and SSL/TLS...